The experience of Pear Therapeutics, Inc. – prior to its collapse – provides insight into reimbursement strategies that may be effective for others in the space, but public and private payors also note some stark realities facing prescription digital therapeutic (PDT) companies in 2023.
“The capital markets are now freezing where money was free for the last 10 years,” noted Jason Parent, director of...